Medical Patent News

RSS

Silence receives U.S. patent entitled, 'Use of Protein Kinase N beta'

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the issuance of patent 4810095 entitled "Use of Protein Kinase N beta" by the Japanese Patent Office.

16 Sep 2011

USPTO issues Certificate of Registration for Echo's SYMPHONY and PRELUDE trademarks

Echo Therapeutics, Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude SkinPrep System for transdermal drug delivery, today announced that the company has received Certificates of Registration from the United States Patent and Trademark Office for its SYMPHONY and PRELUDE trademarks, as used with Echo's tCGM system and mechanical skin ablator, respectively.

15 Sep 2011

Avedro acquires proprietary and patent pending transepithelial ParaCel riboflavin formulation

Avedro, Inc announced today that it has acquired all the intellectual property rights to produce, market, and distribute a breakthrough transepithelial riboflavin formulation based on the research of Roberto Pinelli, MD at the Istituto Laser Microchirurgia Oculare (ILMO) in Brescia, Italy.

14 Sep 2011

Kremers Urban reaches settlement agreement with ALZA over Concerta patent litigation

Kremers Urban Pharmaceuticals Inc. is pleased to announce that it has reached a settlement dismissing all pending litigation arising from its Abbreviated New Drug Application (ANDA) to market an extended release methylphenidate hydrochloride product, for which Concerta is the reference listed drug product. The ANDA is currently under review with FDA.

14 Sep 2011

Impax confirms JALYN patent challenge

Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed in connection with JALYN capsules.

13 Sep 2011

USPTO issues Notice of Allowance for Cortex AMPAKINE molecules to treat respiratory depression

Cortex Pharmaceuticals, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent that protects the use of AMPAKINE molecules for the treatment or prevention of respiratory depression.

25 Aug 2011

USPTO issues Notice of Allowance for Spinal Restoration's Biostat System

Spinal Restoration, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for claims concerning the delivery device and method of use of the Biostat System for the treatment of discogenic low back pain.

24 Aug 2011

Trophos awarded US patent covering use of novel cardioprotective compound

Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).

23 Aug 2011

Federal Circuit affirms dismissal of Illumina's patent infringement lawsuits against Affymetrix

Affymetrix, Inc. today announced that the U. S. Court of Appeals for the Federal Circuit has affirmed the dismissal of the patent infringement lawsuits brought against the Company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020.

From Illumina, Inc. 22 Aug 2011

USPTO issues patent for Spire's nanophotovoltaic device

Spire Corporation, a global solar company providing capital equipment and turn-key manufacturing lines to produce photovoltaic (PV) modules, announced today it has been awarded a patent for its invention of a nanophotovoltaic device which, when applied to biological cells such as cancer, can control and/or limit their growth.

19 Aug 2011

CEL-SCI receives Chinese patent for Multikine cancer drug

CEL-SCI Corporation today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine.

18 Aug 2011

Syndax receives European patent allowance for entinostat to treat metastatic breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the European Patent Office for the patent application titled "N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL) - METHOXYCARBONYL - AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

18 Aug 2011

Mylan confirms Frova patent challenge

Mylan Inc. today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Endo Pharmaceuticals in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Frovatriptan Succinate EQ, 2.5 mg base tablets.

17 Aug 2011

NAI reaches settlement with VPX over beta-alanine patent litigation

Natural Alternatives International, Inc., a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced that it reached a settlement with one of the defendants to litigation pending before the U.S. District Court for the District of Delaware, Vital Pharmaceutical, Inc..

12 Aug 2011

USPTO grants Bion new patent for removal of phosphorus

Bion Environmental Technologies, Inc. announced today that it has been notified by the United States Patent and Trademark Office that the patent application entitled "Micro-Electron Acceptor Phosphorus Accumulating Organisms" has been granted.

12 Aug 2011

Acorda Therapeutics receives U.S. patent allowance for aminopyridine compositions

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has allowed U.S. Patent Application No. 11/102,559 entitled "Method of Using Sustained Release Aminopyridine Compositions."

10 Aug 2011

EPO issues European patent for Rexahn's neurotherapeutic compositions

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office (EPO) has granted European patent No. EP1212055 entitled "Neurotherapeutic compositions comprising a beta-lactam compound."

9 Aug 2011

U.S. District Court rules in favor of POZEN in Treximet patent litigation

POZEN Inc., a pharmaceutical company committed to transforming medicines that transform lives, today announced that the United States District Court for the Eastern District of Texas has issued a favorable verdict in the litigation between POZEN and several generic pharmaceutical companies which had filed Abbreviated New Drug Applications (ANDAs) seeking approval from the U.S. Food and Drug Administration (FDA) to market generic copies of Treximet.

8 Aug 2011

NHS doctors’ use of genetic tests leading to infringement of patent rights

NHS doctors are in trouble for over use of diagnostic genetic tests as these infringe upon patents. The British law now recognizes patents on the application of DNA discoveries. But doctors developing genetic tests in NHS hospitals tend to pay no heed to intellectual property.